Disease severity alone—such as reaching moderate or severe stages of Alzheimer's disease—is not a sufficient reason to stop medication treatment. Instead, authoritative guidelines recommend that decisions about continuing or discontinuing Alzheimer's medications should center on whether the medications are still achieving functional goals and whether the benefits outweigh the burden on quality of life. Many people and families assume that medications stop working in later disease stages and should be discontinued. In fact, clinical trials have demonstrated that combination therapy with cholinesterase inhibitors and memantine continues to show cognitive and functional benefits in moderate-to-severe Alzheimer's disease, and standard clinical practice supports their continued use throughout these disease stages.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the evidence shows about medication benefits in advanced disease
- How to decide whether continuing treatment makes sense
- How to safely discontinue if that decision is made
- Emerging treatments and the case for earlier intervention
- What families and caregivers need to know
- Frequently Asked Questions
What the evidence shows about medication benefits in advanced disease
Standard treatment for moderate-to-severe Alzheimer's includes cholinesterase inhibitors (such as donepezil or rivastigmine) plus memantine, which is FDA-approved specifically for this stage. Memantine works through a different mechanism than cholinesterase inhibitors—it blocks excess glutamate signaling—allowing the two classes to work together. Pooled data from four randomized trials involving 1,549 patients showed that continuing combination therapy produced meaningful
Cognitive Rehabilitation in Dementia: Which Goal Is Being Addressed?”>cognitive
How to decide whether continuing treatment makes sense
The key question is not "How severe is the disease?" but rather "Is this medication still helping achieve what we care about?" Clinical guidance emphasizes that discontinuation is reasonable to consider only when the initial purpose of the drugs is no longer achievable—meaning the person cannot or will not benefit from them anymore—and should always be individualized based on whether the burden of treatment outweighs the quality-of-life benefits. Examples of achievable functional goals might include maintaining ability to eat or communicate, slowing further cognitive decline, keeping someone comfortable at home, or supporting engagement with family.
If medications are supporting any of these, continuing them is justified regardless of disease stage. Conversely, if someone is completely unresponsive and the medications cause side effects or swallowing difficulties, stopping may be the right call.
How to safely discontinue if that decision is made
If discontinuation does make sense for an individual, stopping cholinesterase inhibitors is generally safe and well-tolerated. However, abrupt cessation is not recommended; standard practice calls for tapering the dose gradually over 2 to 4 weeks.
Abrupt stopping can trigger rebound effects and should be avoided. The tapering schedule and any withdrawal monitoring should be directed by the prescribing physician. Because everyone's situation is unique—factors like other medications, swallowing ability, and specific behavioral or cognitive symptoms all matter—the decision and the method need to be tailored to the individual.
Emerging treatments and the case for earlier intervention
Recent advances have shifted the emphasis toward treating Alzheimer's earlier, before it reaches moderate or severe stages. Newer anti-amyloid monoclonal antibodies like lecanemab slow cognitive decline by an average of 27% over 18 months in the mild cognitive impairment and early dementia stages, though they do require amyloid biomarker confirmation and carry a small risk of amyloid-related brain imaging changes.
A 2025 clinical update confirms that earlier intervention—starting at mild cognitive impairment and early dementia—is now the emphasis, with these newer monoclonal antibodies and standard medications working through complementary neurochemical pathways. Cholinesterase inhibitors increase acetylcholine; memantine blocks excess glutamate; anti-amyloid drugs remove plaques. This means the conversation with a doctor should start early, not wait until moderate or severe stages.
What families and caregivers need to know
The most important takeaway is that a diagnosis of moderate or severe Alzheimer's does not mean medication has failed and should stop. Instead, families and caregivers should ask their doctor: "Is this medication helping [person's name] stay comfortable, engaged, or able to do things that matter to them?" If the answer is yes, continuing is supported by evidence. If the answer is no—or if the medication itself is causing problems—then that conversation about adjusting or stopping becomes appropriate, always with a gradual taper rather than an abrupt stop.
Frequently Asked Questions
If my family member has severe Alzheimer's and takes donepezil, should we stop it?
Not because of disease severity alone. Stop only if the medication is not supporting meaningful functional goals (eating, communicating, comfort) and if the benefits no longer outweigh any side effects or burden—a decision made with the doctor.
Are newer drugs like lecanemab available for people with moderate-to-severe dementia?
No; lecanemab and similar anti-amyloid monoclonal antibodies are designed for mild cognitive impairment and early dementia stages, not advanced disease. They require amyloid biomarkers and are most effective when started earlier in the disease course.
